LCM
INZY

Laurion Capital Management’s Inozyme Pharma INZY Stock Holding History

Laurion Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-126,541
Closed -$564K – 448
2024
Q2 		$564K Sell
126,541
-275,656
-69% -$1.34M 0.01% 349
2024
Q1 		$3.08M Sell
402,197
-155,132
-28% -$851K 0.03% 300
2023
Q4 		$2.37M Sell
557,329
-120,000
-18% -$426K 0.02% 284
2023
Q3 		$2.84M Buy
677,329
+426,961
+171% +$2.17M 0.02% 315
2023
Q2 		$1.39M Sell
250,368
-21,432
-8% -$127K 0.01% 340
2023
Q1 		$1.56M Hold
271,800
– – 0.01% 286
2022
Q4 		$285K Hold
271,800
– – ﹤0.01% 374
2022
Q3 		$728K Hold
271,800
– – ﹤0.01% 383
2022
Q2 		$1.3M Buy
271,800
+261,800
+2,618% +$1.14M 0.02% 261
2022
Q1 		$41K Sell
10,000
-3,390
-25% -$20K ﹤0.01% 506
2021
Q4 		$91K Sell
13,390
-57,310
-81% -$495K ﹤0.01% 515
2021
Q3 		$819K Buy
+70,700
New +$1.1M ﹤0.01% 529
2021
Q2 		– Sell
-10,250
Closed -$203K – 815
2021
Q1 		$203K Hold
10,250
– – ﹤0.01% 694
2020
Q4 		$212K Hold
10,250
– – ﹤0.01% 580
2020
Q3 		$269K Buy
+10,250
New +$255K ﹤0.01% 696

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Laurion Capital Management's INZY Position: Q3 2024 in Review

Laurion Capital Management sold out of Inozyme Pharma (INZY) in Q3 2024, closing a stake of 126,541 shares — an estimated $564K sold.

Laurion Capital Management first reported a position in INZY in Q3 2020 and held it in 15 quarters. The position peaked at $3.08M in Q1 2024. 89 funds tracked by Wall St. Rank hold INZY as of Q3 2024.

  • Laurion Capital Management reported no remaining Inozyme Pharma position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 126,541 Inozyme Pharma shares in Q3 2024, an estimated $564K.
  • Laurion Capital Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 15 quarters.
  • Laurion Capital Management's Inozyme Pharma position peaked at $3.08M in Q1 2024.
  • 89 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.